Annex I

List of the names, pharmaceutical forms, strengths of the medicinal products, routes of administration, marketing authorisation holders in the member states

Member State (in EEA)	**Marketing Authorisation Holder**	**Invented name Name**	**Strength**	**Pharmaceutical Form**	**Route of administration**
Denmark	Omrix Biopharmaceuticals S.A., Chaussee de Waterloo 200, B-1640 Rhode-St-Genese Belgium	Quixil	Fibronectin, human: 30 mg Human fibrinogen: 30 mg Arginine hydrochloride 19 mg Acidum tranexamicum 95 mg Glycine 7,9 mg Sodium chloride 7 mg	Solution for sealant	Intralesional use
France	OMRIX Biopharmaceuticals S.A. Chaussée de Waterloo 200 1640 Rhode-St-Genèse Belgium	QUIXIL solution for sealant	1st Component (BAC) Fibrinogen-Fibronectin 40 mg/ml - 60mg/ml Tranexamic acid 85 mg/ml -105mg /ml 2nd Component (Thrombin) Thrombin 800 IU /ml - 1200 IU /ml Calcium chloride: 5,6 mg/ml - 6,2 mg /ml	Solution for sealant	Epilesional use
Italy	OMRIX Biopharmaceuticals S.A. Chaussée de Waterloo 200 1640 Rhode-St-Genèse Belgium	QUIXIL	Fibrinogen and Fibronectin: 40 mg/ml - 60 mg/ml Tranexamic acid: 85 mg/ml -105 mg/ml Thrombin: 800 IU/ml -1,200 IU/ml Calcium Chloride: 5.6 mg/ml – 6.2 mg/ml	Solution for sealant	Epilesional use
United Kingdom	Omrix Biopharmaceuticals S.A., Chaussee de Waterloo 200, B-1640 Rhode-St-Genese Belgium	Quixil	Clottable protein conc: 50mg/ml Thrombin: 1000 IU/ml Calcium chloride: 5.9 mg/ml Tranexamic acid: 95mg/ml	Solution for sealant	Epilesional use